PMID- 28415658
OWN - NLM
STAT- MEDLINE
DCOM- 20180326
LR  - 20220408
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 22
DP  - 2017 May 30
TI  - Diagnostic and prognostic value of blood samples for KRAS mutation identification 
      in lung cancer: a meta-analysis.
PG  - 36812-36823
LID - 10.18632/oncotarget.15972 [doi]
AB  - Circulating tumor DNA (ctDNA) and tumor cells (CTC) are novel approaches for 
      identifying genomic alterations. Thus, we designed a meta-analysis to evaluate 
      the diagnostic value and prognostic significance of a KRAS proto-oncogene, GTPase 
      (KRAS) mutation for lung cancer patients. All included articles were from PubMed, 
      EMBASE, Web of Science and Cochrane Library. Twelve articles that described 1,131 
      patients were reviewed. True positives (TP), false positives (FP), true negatives 
      (TN), and false negatives (FN) were used to calculate pooled sensitivity, 
      specificity, the positive likelihood ratio (PLR), the negative likelihood ratio 
      (NLR), a diagnostic odds ratio (DOR), the area under the curve (AUC) and 
      corresponding 95% confidence intervals (95% CI). PLR is calculated as 
      sensitivity/(1-specificity) and NLR is (1- sensitivity)/specificity. DOR is a 
      measured of diagnostic effectiveness (PLR/NLR). A survival analysis subgroup was 
      also designed to evaluate prognostic significance. Pooled sensitivity, 
      specificity, PLR, NLR, DOR and AUC were 0.79 (95% CI, 0.63-0.89), 0.93 (95% CI, 
      0.89-0.96), 12.13 (92% CI, 7.11-20.67), 0.22 (95% CI, 0.12-0.41), 54.82 (95% CI, 
      23.11-130.09), and 0.95 (95% CI, 0.93-0.96), respectively. KRAS mutation and 
      wild-type hazard ratios for overall survival and progression-free survival were 
      1.37 (95% CI, 1.08-1.66), 1.46 (95% CI, 1.15-1.77) in blood samples, and 1.16 
      (95% CI, 1.03-1.28), 1.28 (95% CI, 1.09-1.46) in tumor tissue.
FAU - Shen, Hongchang
AU  - Shen H
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, P.R. China.
FAU - Che, Keying
AU  - Che K
AD  - Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, P.R. China.
FAU - Cong, Lei
AU  - Cong L
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, P.R. China.
FAU - Dong, Wei
AU  - Dong W
AD  - Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to 
      Shandong University, Jinan, P.R. China.
FAU - Zhang, Tiehong
AU  - Zhang T
AD  - Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, P.R. China.
FAU - Liu, Qi
AU  - Liu Q
AD  - Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, P.R. China.
FAU - Du, Jiajun
AU  - Du J
AD  - Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, P.R. China.
AD  - Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to 
      Shandong University, Jinan, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Circulating Tumor DNA)
RN  - 0 (KRAS protein, human)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
MH  - *Biomarkers, Tumor
MH  - *Circulating Tumor DNA
MH  - DNA Mutational Analysis/methods
MH  - Humans
MH  - Lung Neoplasms/*diagnosis/*genetics/mortality
MH  - *Mutation
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins p21(ras)/*genetics
MH  - Publication Bias
MH  - ROC Curve
MH  - Reproducibility of Results
PMC - PMC5482700
OTO - NOTNLM
OT  - KRAS
OT  - blood
OT  - diagnostic test
OT  - lung cancer
OT  - predictive factor
COIS- CONFLICTS OF INTEREST The authors declare no competing financial interests.
EDAT- 2017/04/19 06:00
MHDA- 2018/03/27 06:00
PMCR- 2017/05/30
CRDT- 2017/04/19 06:00
PHST- 2016/10/09 00:00 [received]
PHST- 2017/02/28 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/03/27 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
PHST- 2017/05/30 00:00 [pmc-release]
AID - 15972 [pii]
AID - 10.18632/oncotarget.15972 [doi]
PST - ppublish
SO  - Oncotarget. 2017 May 30;8(22):36812-36823. doi: 10.18632/oncotarget.15972.